Safety Assessment of Glucagon-Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations - PubMed
3 hours ago
- #GLP-1 receptor agonists
- #tumorigenic risk
- #FAERS database
- GLP-1 receptor agonists (GLP-1RAs) are widely used for Type 2 diabetes treatment but have raised concerns about tumorigenic risks.
- Study analyzed FAERS data (2005-2023) using proportional reporting ratio (PRR) to assess GLP-1RA-related adverse events.
- Most reported adverse events were gastrointestinal disorders (110,451 cases, PRR 2.44), investigative findings (80,126 cases, PRR 2.46), and metabolism disorders (25,236 cases, PRR 2.21).
- Tumor-related cases were fewer (7,457 cases, PRR 0.5), with risks varying by age, gender, and body weight.
- Findings highlight the need for vigilance in specific subpopulations when prescribing GLP-1RAs.